141 related articles for article (PubMed ID: 23052641)
21. RPR120844, a novel, specific inhibitor of coagulation factor Xa inhibits venous thrombosis in the rabbit.
Bostwick JS; Bentley R; Morgan S; Brown K; Chu V; Ewing WR; Spada AP; Pauls H; Perrone MH; Dunwiddie CT; Leadley RJ
Thromb Haemost; 1999 Jan; 81(1):157-60. PubMed ID: 10348709
[TBL] [Abstract][Full Text] [Related]
22. Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding.
Konishi N; Hiroe K; Kawamura M
Thromb Haemost; 2010 Sep; 104(3):504-13. PubMed ID: 20664909
[TBL] [Abstract][Full Text] [Related]
23. Darexaban (YM150), an oral direct factor Xa inhibitor, has no effect on the pharmacokinetics of digoxin.
Kadokura T; Groenendaal D; Heeringa M; Mol R; Verheggen F; Garcia-Hernandez A; Onkels H
Eur J Drug Metab Pharmacokinet; 2014 Mar; 39(1):1-9. PubMed ID: 23754514
[TBL] [Abstract][Full Text] [Related]
24. Rivaroxaban. A novel, oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of thromboembolic disorders.
Perzborn E; Kubitza D; Misselwitz F
Hamostaseologie; 2007 Sep; 27(4):282-9. PubMed ID: 17938768
[TBL] [Abstract][Full Text] [Related]
25. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor.
Perzborn E; Strassburger J; Wilmen A; Pohlmann J; Roehrig S; Schlemmer KH; Straub A
J Thromb Haemost; 2005 Mar; 3(3):514-21. PubMed ID: 15748242
[TBL] [Abstract][Full Text] [Related]
26. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.
Barrett YC; Wang Z; Frost C; Shenker A
Thromb Haemost; 2010 Dec; 104(6):1263-71. PubMed ID: 20978714
[TBL] [Abstract][Full Text] [Related]
27. Determination of rivaroxaban in human plasma samples.
Harenberg J; Erdle S; Marx S; Krämer R
Semin Thromb Hemost; 2012 Mar; 38(2):178-84. PubMed ID: 22422332
[TBL] [Abstract][Full Text] [Related]
28. Comparison of PD0348292, a selective factor Xa inhibitor, to antiplatelet agents for the inhibition of arterial thrombosis.
Karnicki K; Leadley RJ; Baxi S; Peterson T; Wysokinski W; McBane RD
Thromb Haemost; 2008 Apr; 99(4):759-66. PubMed ID: 18392334
[TBL] [Abstract][Full Text] [Related]
29. Nonpeptide factor Xa inhibitors II. Antithrombotic evaluation in a rabbit model of electrically induced carotid artery thrombosis.
Wong PC; Crain EJ; Knabb RM; Meade RP; Quan ML; Watson CA; Wexler RR; Wright MR; Slee AM
J Pharmacol Exp Ther; 2000 Oct; 295(1):212-8. PubMed ID: 10991981
[TBL] [Abstract][Full Text] [Related]
30. [Rivaroxaban: mode of action].
Drouet L
Ann Fr Anesth Reanim; 2008 Dec; 27 Suppl 3():S9-15. PubMed ID: 19185786
[TBL] [Abstract][Full Text] [Related]
31. Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity.
Graff J; von Hentig N; Misselwitz F; Kubitza D; Becka M; Breddin HK; Harder S
J Clin Pharmacol; 2007 Nov; 47(11):1398-407. PubMed ID: 17873238
[TBL] [Abstract][Full Text] [Related]
32. Rivaroxaban: a novel, oral, direct factor Xa inhibitor.
Abrams PJ; Emerson CR
Pharmacotherapy; 2009 Feb; 29(2):167-81. PubMed ID: 19170587
[TBL] [Abstract][Full Text] [Related]
33. Effect of food on the pharmacokinetics of darexaban, an oral direct factor Xa inhibitor, in healthy Japanese subjects.
Kadokura T; Taniuchi Y; Inoue H; Saito M; Iwahana M; Yamada S; Urae A; Nakamura M
Int J Clin Pharmacol Ther; 2013 Mar; 51(3):200-6. PubMed ID: 23211396
[TBL] [Abstract][Full Text] [Related]
34. Open-label, randomized study of the effect of rivaroxaban with or without acetylsalicylic acid on thrombus formation in a perfusion chamber.
Wolzt M; Gouya G; Kapiotis S; Becka M; Mueck W; Kubitza D
Thromb Res; 2013 Aug; 132(2):240-7. PubMed ID: 23786894
[TBL] [Abstract][Full Text] [Related]
35. Interference of rivaroxaban in one-stage and chromogenic factor VIII:C assays.
Tichelaar V; de Jong H; Nijland H; Kluin-Nelemans H; Meijer K; Mulder A
Thromb Haemost; 2011 Nov; 106(5):990-2. PubMed ID: 21901233
[No Abstract] [Full Text] [Related]
36. Clinical pharmacokinetics, pharmacodynamics, safety and tolerability of darexaban, an oral direct factor Xa inhibitor, in healthy Caucasian and Japanese subjects.
Kadokura T; Kashiwa M; Groenendaal D; Heeringa M; Mol R; Verheggen F; Garcia-Hernandez A; Onkels H
Biopharm Drug Dispos; 2013 Nov; 34(8):431-41. PubMed ID: 23929659
[TBL] [Abstract][Full Text] [Related]
37. Oral direct factor Xa inhibitors, with special emphasis on rivaroxaban.
Mousa SA
Methods Mol Biol; 2010; 663():181-201. PubMed ID: 20617418
[TBL] [Abstract][Full Text] [Related]
38. Antithrombotic efficacy of a recombinant nematode anticoagulant peptide (rNAP5) in canine models of thrombosis after single subcutaneous administration.
Rebello SS; Blank HS; Rote WE; Vlasuk GP; Lucchesi BR
J Pharmacol Exp Ther; 1997 Oct; 283(1):91-9. PubMed ID: 9336312
[TBL] [Abstract][Full Text] [Related]
39. Rivaroxaban attenuates leukocyte adhesion in the microvasculature and thrombus formation in an experimental mouse model of type 2 diabetes mellitus.
Iba T; Aihara K; Yamada A; Nagayama M; Tabe Y; Ohsaka A
Thromb Res; 2014 Feb; 133(2):276-80. PubMed ID: 24351208
[TBL] [Abstract][Full Text] [Related]
40. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.
Eriksson BI; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Muehlhofer E; Dierig C; Misselwitz F; Kälebo P;
Circulation; 2006 Nov; 114(22):2374-81. PubMed ID: 17116766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
